Annual report pursuant to Section 13 and 15(d)

NON CONTROLLING INTEREST

NON CONTROLLING INTEREST

12 Months Ended

Dec. 31, 2019

On July 28, 2016, the Company formed BioCorRx Pharmaceuticals, Inc., a Nevada Corporation, for the purpose of developing certain business lines. In connection with the formation, the, the newly formed sub issued 24.2% ownership to current or former officers of the Company with the Company retaining 75.8%. From inception through December 31, 2017, there were no significant transactions. There were certain licensing rights with a carrying value of $250,000 and no significant liabilities in BioCorRx Pharmaceuticals, Inc. In 2018, BioCorRx Pharmaceuticals, Inc. began operations.

A reconciliation of the BioCorRx Pharmaceuticals, Inc. non-controlling loss attributable to the Company:

Net loss attributable to the non-controlling interest for the year ended December 31, 2019:

Net loss	$	(35,914	)
Average Non-controlling interest percentage of profit/losses		24.2	%
Net loss attributable to the non-controlling interest	$	(8,691	)

Net loss attributable to the non-controlling interest for the year ended December 31, 2018:

Net loss	$	(299,533	)
Average Non-controlling interest percentage of profit/losses		24.2	%
Net loss attributable to the non-controlling interest	$	(72,487	)

The following table summarizes the changes in non-controlling interest for the year ended December 31, 2019:

Balance, December 31, 2018	$	(72,487	)
Net loss attributable to the non-controlling interest		(8,691	)
Balance, December 31, 2019		(81,178	)

The following table summarizes the changes in non-controlling interest for the year ended December 31, 2018:

Balance, December 31, 2017		-
Net loss attributable to the non-controlling interest		(72,487	)
Balance, December 31, 2018	$	(72,487	)